中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
9期
37-38
,共2页
来氟米特%硫酸羟氯喹%狼疮性肾炎%血脂
來氟米特%硫痠羥氯喹%狼瘡性腎炎%血脂
래불미특%류산간록규%랑창성신염%혈지
leflunomide%hydroxychloroquine sulfate%lupus nephritis%blood lipid
目的：探讨来氟米特（LEF）和硫酸羟氯喹( HCQ )对狼疮性肾炎患者血脂水平影响的差异。方法选取2010年3月至2014年3月86例维持治疗期狼疮性肾炎患者，随机分为两组，各43例，分别予LEF和HCQ治疗，观察3个月，比较两组治疗前后血脂水平。结果 LEF组治疗前后血脂水平无显著差异（ P＞0.05）；HCQ组治疗前后三酰甘油（TG）分别为（1.98±0.33）mmol/L比（1.74±0.36）mmol/L （ P＜0.01)，总胆固醇（TC）为（4.69±0.65）mmol/L比（4.39±0.58）mmol/L（ P＜0.05）；治疗前两组间各血脂成分无显著差异（ P＞0.05），治疗后 LEF 组和 HCQ组 TG 分别为(1.91+0.35）mmol/L 比（1.74±0.36）mmol/L（ P＜0.05)，TC 分别为(4.71±0.67) mmol/L 比（4.39±0.58）mmol/L（ P＜0.05)。结论硫酸羟氯喹和来氟米特均能缓解狼疮肾炎患者的病情，但前者可降低患者血脂水平，从而减少心血管事件发生的风险。
目的：探討來氟米特（LEF）和硫痠羥氯喹( HCQ )對狼瘡性腎炎患者血脂水平影響的差異。方法選取2010年3月至2014年3月86例維持治療期狼瘡性腎炎患者，隨機分為兩組，各43例，分彆予LEF和HCQ治療，觀察3箇月，比較兩組治療前後血脂水平。結果 LEF組治療前後血脂水平無顯著差異（ P＞0.05）；HCQ組治療前後三酰甘油（TG）分彆為（1.98±0.33）mmol/L比（1.74±0.36）mmol/L （ P＜0.01)，總膽固醇（TC）為（4.69±0.65）mmol/L比（4.39±0.58）mmol/L（ P＜0.05）；治療前兩組間各血脂成分無顯著差異（ P＞0.05），治療後 LEF 組和 HCQ組 TG 分彆為(1.91+0.35）mmol/L 比（1.74±0.36）mmol/L（ P＜0.05)，TC 分彆為(4.71±0.67) mmol/L 比（4.39±0.58）mmol/L（ P＜0.05)。結論硫痠羥氯喹和來氟米特均能緩解狼瘡腎炎患者的病情，但前者可降低患者血脂水平，從而減少心血管事件髮生的風險。
목적：탐토래불미특（LEF）화류산간록규( HCQ )대랑창성신염환자혈지수평영향적차이。방법선취2010년3월지2014년3월86례유지치료기랑창성신염환자，수궤분위량조，각43례，분별여LEF화HCQ치료，관찰3개월，비교량조치료전후혈지수평。결과 LEF조치료전후혈지수평무현저차이（ P＞0.05）；HCQ조치료전후삼선감유（TG）분별위（1.98±0.33）mmol/L비（1.74±0.36）mmol/L （ P＜0.01)，총담고순（TC）위（4.69±0.65）mmol/L비（4.39±0.58）mmol/L（ P＜0.05）；치료전량조간각혈지성분무현저차이（ P＞0.05），치료후 LEF 조화 HCQ조 TG 분별위(1.91+0.35）mmol/L 비（1.74±0.36）mmol/L（ P＜0.05)，TC 분별위(4.71±0.67) mmol/L 비（4.39±0.58）mmol/L（ P＜0.05)。결론류산간록규화래불미특균능완해랑창신염환자적병정，단전자가강저환자혈지수평，종이감소심혈관사건발생적풍험。
Objective To compare the difference in the influences of leflunomide and hydroxychloroquine sulfate on blood lipid levels in the patients with lupus nephritis. Methods 86 patients with lupus nephrites treated by the maintenance treatment from March 2010 to March 2014 were randomly assigned to the leflunomide ( LEF ) group and the hydroxychloroquine sulfate ( HCQ ) group,each of them were 43 Cases. The two groups were respectively treated by leflunomide and hydroxychloroquine sulfate for 3 months. The blood lipid level before and after treatment were examined and compared between the two groups. Results The blood lipid levels in the LEF group has no statistical difference between before and after treatment ( P > 0. 05 );the blood lipid level after treatment in HCQ group has statistically significant statistical difference compared with before treatment [ triglyceride ( TG ): ( 1. 98 ± 0. 33 ) vs. ( 1. 74 ± 0. 36 ) mmol/L, P < 0. 01; total cholesterol ( TC ): ( 4. 69 ± 0. 65 ) vs. ( 4. 39 ± 0. 58 ) mmol/L, P < 0. 05 ]; the blood lipid levels before treat-ment had no statistically significant difference between the LEF group and the HCQ group ( P > 0. 05 ) , but the blood TG and TC levels after treatment had statistically significant differences between the two groups [ TG: ( 1. 91+0. 35 ) mmol/L vs. ( 1. 74 ± 0. 36 ) mmol/L, P < 0. 05;TC: ( 4. 71 ± 0. 67 ) mmol/L vs. ( 4. 39 ± 0. 58 ) mmol/L, P < 0. 05 ] . Conclusion Hydroxychloroquine sulfate and leflunomide all relieve but the former can decrease the patient ’ s lipid level, thus reduce the cardiovascular risk.
